U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/075,257 Application Number INFORMATION DISCLOSURE Filing Date February 15, 2002 STATEMENT BY APPLICANT First Named Inventor REITER Yoram Art Unit (use as many sheets as necessary) Examiner Name of 3 Attorney Docket Number 02/23338 1 Sheet U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Examiner Cite Document Number Publication Date Name of Patentee or DD-MMM-YYYY Applicant of Cited Document Initials* Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (if known)} 2003/0003535 02-Jan-2003 Reiter 2 2004/0086960 06-May-2004 Reiter 03-Jun-1997 Altman et al. 3 5,635,363 02-Nov-1999 Mottez et al. 4 5,976,551 04-Jan-2000 Mottez et al. 5 6,011,146 28-Nov-2000 Abastado et al. 6,153,408 6 FOREIGN PATENT DOCUMENTS Cite Pages, Columns, Lines, Examiner Initials* Foreign Patent Documents Publication Date Name of Patentee or Where Relevant Passages T DD-MMM-YYYY or Relevant Figures Applicant of Cited Document Country Code3-Number4-Kind Code5 (if known) Appear 7 WO 01/72768 04-Oct-2001 Reiter

Date

Considered

Examiner

Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must procede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to flie (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/075.257 February 15, 2002 Filing Date INFORMATION DISCLOSURE First Named Inventor REITER Yoram STATEMENT BY APPLICANT Group Art Unit Examiner Name (use as many sheets as necessary) 02/23338 Attorney Docket Number Sheet OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), No.1 Initials T^2 publisher, city and/or country where published. Abastado et al. "Dimerization of Soluble Major Histocompatibility Complex-Peptide Complexes Is Sufficient for Activation of T Cell Hybridoma and Induction of Unresponsiveness", Journal of Experimental Medicine, P.439-447, 1995. Abstract. P.439, Col.2, P.440, Col.1, § 1. 9 Bousso et al. "Enrichment of Antigen-Specific T Lymphocytes by Panning on Immobilized MHC-Peptide Complexes", Immunology Letters, 59(2): 85-91, 1997. Abstract. P.86, Col.1. Denkberg et al, "Recombinant Human Single-Chain MHC-Peptide Complexes 10 Made From E. Coli by In Vitro Refolding: Functional Single-Chain MHC-Peptide Complexes and Tetramers With Tumor Associated Antigens", European Journal of Immunology, 30(12): 3522-3532, 2000. Abstract. P.3524, Col.1, § 2, From Garboczi et al. "HLA-A2-Peptide Complexes: Refolding and Crystallization of 11 Molecules Expressed in Escherichia Coli and Complexed With Single Antigenic Peptides", Proc. Natl. Acad. Sci. USA, 89: 3429-3433, 1992. Abstract. P.3429, Col.1, § 1. 12 Kourilsky et al. "Immunological Issues in Vaccine Trials: T-Cell Responses", Preclinical and Clinical Development of New Vaccines, 95: 117-124, 1998. 13 Lee et al. "Functional Cell Surface Expression by A Recombinant Single-Chain Class I Major Histocompatibility Complex Molecule With A Cis-Active Beta 2-Microglobulin Domain", European Journal of Immunology, 24(11): 2633-2639, 14 Ogg et al. "HLA-Peptide Tetrameric Complexes", Current Opinion in Immunology, 10: 393-396, 1998. Ojcius et al. "Dissociation of the Peptide-MHC Class I Complex Limits the 15 Binding Rate of Exogenous Peptide", Journal of Immunology, 151(11): 6020-6026, 1993. 16 Parker et al. "Peptide Binding to HLA-A2 and HLA-B27 Isolated From Eschericia Coli", The Journal of Biological Chemistry, 267(8): 5451-5459, 1992. 17 Parker et al. "Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2", Journal of Immunology, 149(11): 3580-3587, 1992. 18 Patamawenu et al. "Generation of Functional HLA-A2 Molecules Covalently Attached to Antigenic Peptides", Thesis (Master of Science in Biomedical Science), University of Maryland, 1988. Abstract. 19 Rammensee et al. "MHC Molecules as Peptide Receptors", Current Opinion Immunology, 5(1): 35-44, 1993.

Date

Considered

Examiner

Signature

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 97/3 L/2006, OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known			
	Su	ostitute for form 1449A/PTO			Application Number	10/075,257		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	15-Feb-2002 REITER Yoram			
				First Named Inventor				
31.	AILNI	ENI BY APPLU	CANI		Art Unit			
	(use as	many sheets as necessa	ry)		Examiner Name			
Sheet		3 Of	f 3	3	Attorney Docket Number	02/23338		
, ,		OTHER PRIOR AR	T – NON P	ATE	NT LITERATURE DOCU	MENTS	-	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the						
	20	Sylvester-Hvid et al. "A Single-Chain Fusion Molecule Consisting of Peptide, Major Histocompatibility Gene Complex Class I Heavy Chain and ?2- Microglobulin Can Fold Partially Correctly, But Binds Peptide Inefficiently", Scandinavian Journal of Immunology, 50(4): 355-352, 1999. P.358, Col.1, Fig.2, P.358, Col.2, ff, P.357, Col.1, § 1.						
	21	Tafuro et al. "Reconstitution of Antigen Presentation in HLA Class I-Negative Cancer Cells With Peptide-?2M Fusion Molecules", European Journal of Immunology, 31(2): 440-449, 2001. Abstract. P.442, Fig.1.						
	22	Toshitani et al. "Expression of A Single-Chain HLA Class I Molecule in A Human Cell Line: Presentation of Exogenous Peptide and Processed Antigen to Cytotoxic T Lymphocytes", Proc. Natl. Acad. Sci. USA, 93(1): 236-240, 1996. Abstract, P.237, Col.2, Last §, Fig.1, P.236, Col.2, P.237, Col.2, § 2 From the Bottom, P.240, §1. Urban et al. "The Discovery and Use of HLA-Associated Epitopes as Drugs", Critical Reviews in Immunology, 17(5-6): 387-397, 1997. Zajac et al. "Generation of Tumoricidal Cytotoxic T Lymphocytes From Healthy Donors, After In-Vitro Stimulation With A Replicatin-Incompetent Vaccina Virus Encoding Mart-1/Melan-A 27-35 Epitope", International Journal of Cancer, 71: 491-496, 1997.						
	23							
	24							
			•					
	-							
Examiner					Date			

	Signature	Considered					
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.							

Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional).

Applicant's unique creation designation frames (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450